Galmed Pharmaceuticals Ltd. (GLMD) Q1 2021 Earnings Call

Investor webinar replay

Replay transcript excerpt

and welcome to the GALMED conference call to discuss financial results for the first quarter 2021. Today's conference is being recorded. Before we begin, please note that we will be making certain forward-looking statements on today's call, including those regarding financial results, statements, and forecasts regarding anticipated timelines and expectations with respect to our regulatory and clinical development programs. as well as other statements that relate to future events. These statements are based on the beliefs and expectations of management as of today, and actual results, trends, timelines, and projections relating to our financial position and projected development programs and pipeline could differ materially. We urge all investors to read carefully the risks and uncertainties disclosed in our filings with the SEC, including, without limitation, the risks under the heading Risk Factors described in our most recent annual report on Form 20-F, filed with the SEC. SALMED assumes no obligation to update any forward-looking statements or information, which speaks as of to their respective dates only. I will now turn the call over to Alan Vajaroff, President and Chief Executive Officer. Alan, please go ahead. Thank you, Donna. Good morning, and thank you for joining us on today's conference call. I'm pleased to be here today with our Chief Scientific Officer, Dr. Liata Yardeni, our Chief Financial Officer, Zohaish Chancellor, to provide you with an update on our clinical development programs, as well as report to you on our financial results for the first quarter of 2021. As always, we will be happy to take any questions you may have at the conclusion of our prepared remarks. As we have held our investors' year-end poll only a few weeks ago, my report to you ...